Literature DB >> 19125353

Effects of puerarin on receptor for advanced glycation end products in nephridial tissue of streptozotocin-induced diabetic rats.

Jian Guo Shen1, Mei Fen Yao, Xiao Chan Chen, Yun Fei Feng, Yu Hong Ye, Zhong Hang Tong.   

Abstract

To explore the effects of puerarin on mRNA expression of advanced glycation end products (AGE) specIfic cellular receptor (RAGE) in renal cortex of diabetic rats induced by streptozotocin (STZ). We induced Diabetic rats by an intraperitoneal injection of STZ in Sprague-Dawley (SD) rats. 30 male SD rats were randomly divided into 3 groups, diabetes adding puerarin group (DP group, n = 11, intraperitoneal injection of puerarin 100 mg/kg d), Diabetes group (D group, n = 11) and normal control group (C group, n = 8). The body weight (BW) and blood glucose (BG) were measured every 2 weeks. eight weeks later, all rats were sacrificed and the expression of RAGE mRNA was detected in renal cortex by reverse transcription-polymerase chain reaction (RT-PCR), respectively, and renal AGEs content was determined by fluorescence microscopy. Compared with those of control group, the BW and BG were lower in DP group and D group at 8th week (P < 0.01). RAGE/beta-actin ratio were 0.263 +/- 0.023, 0.435 +/- 0.010, 0.141 +/- 0.045, respectively, in DP group, D group and C group, and there was significant difference between every two groups (P < 0.01). The renal AGEs fluorescence intensity of DP group was weaker than D group, stronger than C group. Puerarin can protect the renal tissue from the impairment of hyperglycemia and AGE by decreasing AGEs contents and inhibiting of the expression of RAGE mRNA in the kidney.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125353     DOI: 10.1007/s11033-008-9438-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  14 in total

1.  Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?

Authors:  Melinda T Coughlan; Vicki Thallas-Bonke; Josefa Pete; David M Long; Anna Gasser; David C K Tong; Maryann Arnstein; Suzanne R Thorpe; Mark E Cooper; Josephine M Forbes
Journal:  Endocrinology       Date:  2006-11-16       Impact factor: 4.736

2.  Metabolic activation promotes estrogenic activity of the phytoestrogen-rich plant.

Authors:  Wichai Cherdshewasart; Suttijit Sriwatcharakul
Journal:  Maturitas       Date:  2008-03-04       Impact factor: 4.342

3.  Puerarin acts through brain serotonergic mechanisms to induce thermal effects.

Authors:  Fu-Shin Chueh; Ching-Ping Chang; Chung-Ching Chio; Mao-Tsun Lin
Journal:  J Pharmacol Sci       Date:  2004-12-03       Impact factor: 3.337

4.  RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.

Authors:  Khin-Mar Myint; Yasuhiko Yamamoto; Toshio Doi; Ichiro Kato; Ai Harashima; Hideto Yonekura; Takuo Watanabe; Harumichi Shinohara; Masayoshi Takeuchi; Koichi Tsuneyama; Noriyoshi Hashimoto; Masahide Asano; Shin Takasawa; Hiroshi Okamoto; Hiroshi Yamamoto
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

5.  Constituents of the roots of Pueraria lobata inhibit formation of advanced glycation end products (AGEs).

Authors:  Jong Min Kim; Yun Mi Lee; Ga Young Lee; Dae Sik Jang; Ki Hwan Bae; Jin Sook Kim
Journal:  Arch Pharm Res       Date:  2006-10       Impact factor: 4.946

6.  Puerarin reduces increased c-fos, c-jun, and type IV collagen expression caused by high glucose in glomerular mesangial cells.

Authors:  Cai-ping Mao; Zhen-lun Gu
Journal:  Acta Pharmacol Sin       Date:  2005-08       Impact factor: 6.150

7.  Major isoflavonoid contents of the 1-year-cultivated phytoestrogen-rich herb, Pueraria mirifica.

Authors:  Wichai Cherdshewasart; Suttijit Sriwatcharakul
Journal:  Biosci Biotechnol Biochem       Date:  2007-10-07       Impact factor: 2.043

8.  Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice.

Authors:  Mi Ja Chung; Nak-Ju Sung; Cheon-Seok Park; Dong-Keon Kweon; Alberto Mantovani; Tae-Wha Moon; Sung-Joon Lee; Kwan-Hwa Park
Journal:  Eur J Pharmacol       Date:  2007-10-05       Impact factor: 4.432

9.  Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats.

Authors:  Feng-Lin Hsu; I-Min Liu; Daih-Huang Kuo; Wang-Chuan Chen; Hui-Chen Su; Juei-Tang Cheng
Journal:  J Nat Prod       Date:  2003-06       Impact factor: 4.050

Review 10.  AGE, RAGE, and ROS in diabetic nephropathy.

Authors:  Adeline L Y Tan; Josephine M Forbes; Mark E Cooper
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

View more
  5 in total

1.  Acute and Chronic Kudzu Improves Plasma Glucose Tolerance in Non-Diabetic CD-1 Mice.

Authors:  Scott Carlson; Jeevan K Prasain; Ning Peng; Yanying Dai; J Michael Wyss
Journal:  J Endocrinol Diabetes Mellit       Date:  2014

Review 2.  Effects of three flavonoids from an ancient traditional Chinese medicine Radix puerariae on geriatric diseases.

Authors:  Sijia Zhang; Jue Wang; Haiping Zhao; Yumin Luo
Journal:  Brain Circ       Date:  2018-12-31

Review 3.  Effects of puerarin on chronic inflammation: Focus on the heart, brain, and arteries.

Authors:  Li Zhang; Lisheng Liu; Mingyi Wang
Journal:  Aging Med (Milton)       Date:  2021-12-15

Review 4.  Molecular Mechanism of Puerarin Against Diabetes and its Complications.

Authors:  Yi-Ling Bai; Ling-Ling Han; Jun-Hui Qian; Hao-Zhong Wang
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

5.  Epigenetic changes caused by diabetes and their potential role in the development of periodontitis.

Authors:  Yanfen Li; Zhibin Du; Xiaoting Xie; Yangheng Zhang; Huifen Liu; Ziqian Zhou; Jing Zhao; Ryan Sb Lee; Yin Xiao; Saso Ivanoviski; Fuhua Yan
Journal:  J Diabetes Investig       Date:  2021-01-26       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.